Polymorphisms of the stem cell marker gene are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients.

OBJECTIVES

To evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in (A>C, T>A, C>G, and C>T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients.

DESIGN

Retrospective cohort study.

SETTING

Department of General Surgery, in a general hospital, Henan Province, China.

PARTICIPANTS

NSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion. Those participants who were pregnant or breastfeeding, had a previous history of cancer, had other primary tumours, or who had had primary tumours of the skin and nasopharynx, were excluded from the study.

OUTCOME MEASURES

The primary endpoint was OS, which was calculated from the date of enrolment until the date of death or date of last follow-up.

RESULTS

There was a total of 1383 participants, with a median age of 63 years; 726 (52.5%) were male. Compared with the AA genotype, the variant AC/CC genotypes were independently associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype). Higher hazard ratios for associations between polymorphism and OS were observed in patients with adjuvant chemotherapy (HR 1.86, 95% CI 1.52 to 2.26) and radiotherapy for curative intent (HR 1.90, 95% CI 1.55 to 2.33).

CONCLUSIONS

The study confirmed the significant association between the SNP of CD133 and OS of NSCLC patients. Larger population-based studies in different ethnic groups are necessary to further validate the role and mechanisms of in NSCLC.